



GP 1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
MAY 07 2001
TECH CENTER 1600/2900

Applicant: Gregg B. Fields, et al. Group Art Unit: 1642
Serial No.: 09/529,691 Examiner: S. Rawlings
Filed: August 29, 2000 (Int'l Filing Date: Oct. 22, 1998) Docket No.: 110.00680101
Title: INHIBITION OF TUMOR CELL ADHESION TO TYPE IV COLLAGEN

Assistant Commissioner for Patents
BOX SEQUENCE
Washington, D.C. 20231

We are transmitting the following documents along with this Transmittal Sheet:

- ☒ **Small entity status is entitled to be asserted in the above-identified application.**
- ☒ A return postcard.
- ☐ A Petition for Extension of Time for __ month(s) and a check in the amount of \$__ for the required fee.
- ☐ An Information Disclosure Statement (__ pgs); copies of __ applications; 1449 forms (__ pgs); and copies of __ documents cited on the 1449 forms.
- ☐ A check in the amount of \$__, representing __.
- ☒ Preliminary Amendment and Response to Notice to Comply with Sequence Requirements (4 pgs total, including Appendix A (1 pg)); Sequence Listing (2 pgs); Computer-readable version of Sequence Listing (1 diskette); Copy of Notice to Comply with Requirements.
- ☐ Other:
- ☐ Amendment ☐ No Additional fee is required. ☐ The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$9 =	
Independent Claims				x \$40 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$135 Here →					
Total Additional Claim Fees Required					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Transmittal Letter and the paper(s), as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, BOX SEQUENCE, Washington, D.C. 20231, on this 30th day of April, 2001.

MUETING, RAASCH & GEBHARDT, P.A.
Customer Number: 26813

By:
Name: David L. Provence
Reg. No.: 43,022
Direct Dial: 612-305-1005
Facsimile: 612-305-1228



RECEIVED

MAY 07 2001

TECH CENTER 1600/2900

PATENT
Docket No. 110.00680101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Gregg B. Fields, et al.) Group Art Unit: 1642
Serial No.: 09/529,691) Examiner: S. Rawlings
Filed: August 29, 2000) Int'l Filing Date: 22 October 1998
For: INHIBITION OF TUMOR CELL ADHESION TO TYPE IV COLLAGEN

9/C
1CD
5-12-01

PRELIMINARY AMENDMENT AND
RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE REQUIREMENTS

BOX SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Please amend the above-referenced patent application as follows:

IN THE SPECIFICATION

Please replace the paragraph beginning at page 3, line 5, with the following rewritten paragraph. Per 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate the changes made.

C1 - Schnolzer and Kent (M. Schnolzer et al., *Science*, 256, 221-225 (1992)) synthesized all-L and all-D HIV-1 proteases, then examined the chiral specificity of the two enzymes using the substrate 2-aminobenzoyl-Thr-Ile-Nle-Nph-Gln-Arg-NH₂ (where Nph is nitrophenylalanine) (SEQ ID NO:2). The synthetic all-L enzyme cleaved only the all-L, not the all-D, version of 2-aminobenzoyl-Thr-Ile-Nle-Nph-Gln-Arg-NH₂ (SEQ ID NO:2) while the synthetic all-D enzyme cleaved only the all-D substrate. The chiral specificity of enzymes was established by these results.